Altered plasma albumin characteristics and lymphocyte populations in gastrointestinal cancer patients: Detection using modified fluorescence responses

Abstract

The fluorescent probe ABM (an amino derivative of benzanthrone) developed at Riga Technical University (Riga, Latvia) was used to characterize the blood plasma albumin of cancer patients (46 gastrointestinal cancer patients—30 with colorectal cancer in Stages II–IV and 16 with gastric cancer in Stage III) and of healthy controls. The fluorescence intensity of ABM in the blood plasma decreased from the control mean value and showed specific differences in the patients before (i.e., 24 hr pre-) and after (i.e., 10 day post-) they underwent a medically indicated surgical treatment, i.e., a gastric resection or gastroectomy for patients in the gastric cancer group or a colorectal resection for patients in the colorectum cancer group. The significant decrease in the ABM fluorescence in the blood plasma could be explained, in part, by a diminished binding capacity of the albumin of these patients. In fact, before surgery, there was a strong reduction in binding constant (Ka) value for the probe observed in the plasma samples from these patients as compared with the value obtained with the plasma of the healthy donors. The lymphocyte distribution among the subsets also differed between the groups. Surgical treatment affected several immunological parameters and appeared to elevate the functional status of lymphocytes. Interestingly, the ABM fluorescence in the blood plasma was also seen to correlate with select immunological parameters (CD4+:CD8+ ratios, levels of CD38+ cells, etc.) both before and after the patients’ operations. The results in the present study suggest that measures of ABM fluorescence intensity values for plasma albumin and/or especially of lymphocytes (as reflections of their functional activity) might be a useful tool in the evaluation of the immune status of gastrointestinal cancer patients.